Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Octavia M. Peck Palmer"'
Autor:
Matthew B. Rogers, Ashley Harner, Megan Buhay, Brian Firek, Barbara Methé, Alison Morris, Octavia M. Peck Palmer, Susan B. Promes, Robert L. Sherwin, Lauren Southerland, Alexandre R. Vieira, Sachin Yende, Michael J. Morowitz, David T. Huang
Publikováno v:
PLoS ONE, Vol 19, Iss 1 (2024)
Externí odkaz:
https://doaj.org/article/27ed1be248d349bba86119c4b837a437
Autor:
Sarah E. Wheeler, Li Liu, Harry C. Blair, Richard Sivak, Nancy Longo, Jeffery Tischler, Kathryn Mulvey, Octavia M. Peck Palmer
Publikováno v:
BMC Research Notes, Vol 10, Iss 1, Pp 1-7 (2017)
Abstract Objective Thyroglobulin (Tg) measurements assess recurrence in post-thyroidectomy thyroid cancer patients. Tg measurements by enzyme immunoassays (EIA) can be falsely elevated by interference from Tg autoantibodies (TgAb). Radioimmunoassay (
Externí odkaz:
https://doaj.org/article/a1830f8f5c2a4af68e11fa5243a6092e
Autor:
David T. Huang, Erin K. McCreary, J. Ryan Bariola, Richard J. Wadas, Kevin E. Kip, Oscar C. Marroquin, Stephen Koscumb, Kevin Collins, Judith A. Shovel, Mark Schmidhofer, Mary Kay Wisniewski, Colleen Sullivan, Donald M. Yealy, Meredith Axe, David A. Nace, Ghady Haidar, Tina Khadem, Kelsey Linstrum, Graham M. Snyder, Christopher W. Seymour, Stephanie K. Montgomery, Bryan J. McVerry, Lindsay Berry, Scott Berry, Russell Meyers, Alexandra Weissman, Octavia M. Peck-Palmer, Alan Wells, Robert Bart, Debbie L. Albin, Tami Minnier, Derek C. Angus
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-3 (2021)
Abstract Objectives The primary objective is to evaluate the comparative effectiveness of COVID-19 specific monoclonal antibodies (mABs) with US Food and Drug Administration (FDA) Emergency Use Authorization (EUA), alongside UPMC Health System effort
Externí odkaz:
https://doaj.org/article/11a244af7e12486d9480802ecb95cd0a
Publikováno v:
The Journal of Applied Laboratory Medicine. 8:655-659
Autor:
Nadia Ayala-Lopez, Octavia M Peck Palmer, M Laura Parnas, Lakshmi V Ramanathan, Zahra Shajani-Yi
Publikováno v:
Clinical Chemistry. 68:754-760
Autor:
Kathryn L. Kapp, Albert B. Arul, Kevin C. Zhang, Liping Du, Sachin Yende, John A. Kellum, Derek C. Angus, Octavia M. Peck-Palmer, Renã A. S. Robinson
Publikováno v:
Molecular Omics. 18:923-937
Intra-abdominal infection is a common cause of sepsis, and intra-abdominal sepsis leads to ∼156 000 U.S. deaths annually. African American/Black adults have higher incidence and mortality rates from sepsis compared to Non-Hispanic White adults. A l
Autor:
Octavia M. Peck Palmer, Amy Lukanski, P. Nathan Enick, Alan Wells, Jana L. Jacobs, Michele D. Sobolewski, David A. Nace, April L. Kane, Kevin E. Kip, Melissa Crandall, John W. Mellors, Paula L Kip, Katie Mulvey, Kevin D. McCormick, Michael R. Shurin
Publikováno v:
Journal of the American Medical Directors Association
Objective COVID-19 disproportionately impacts residents in long-term care facilities. Our objective was to quantify the presence and magnitude of antibody response in vaccinated, older adult residents at assisted living, personal care, and independen
Publikováno v:
Clinical Chemistry. 69:110-111
Autor:
Octavia M Peck Palmer, Dina N Greene
Publikováno v:
The Journal of Applied Laboratory Medicine. 7:406-408
Autor:
Erin K. McCreary, J. Ryan Bariola, Tami E. Minnier, Richard J. Wadas, Judith A. Shovel, Debbie Albin, Oscar C. Marroquin, Kevin E. Kip, Kevin Collins, Mark Schmidhofer, Mary Kay Wisniewski, David A. Nace, Colleen Sullivan, Meredith Axe, Russell Meyers, Alexandra Weissman, William Garrard, Octavia M. Peck-Palmer, Alan Wells, Robert D. Bart, Anne Yang, Lindsay R. Berry, Scott Berry, Amy M. Crawford, Anna McGlothlin, Tina Khadem, Kelsey Linstrum, Stephanie K. Montgomery, Daniel Ricketts, Jason N. Kennedy, Caroline J. Pidro, Ghady Haidar, Graham M. Snyder, Bryan J. McVerry, Donald M. Yealy, Derek C. Angus, Anna Nakayama, Rachel L. Zapf, Paula L. Kip, Christopher W. Seymour, David T. Huang
Publikováno v:
Contemporary clinical trials. 119
Monoclonal antibodies (mAb) that neutralize SARS-CoV-2 decrease hospitalization and death compared to placebo in patients with mild to moderate COVID-19; however, comparative effectiveness is unknown. We report the comparative effectiveness of bamlan